Statin treatment before percutaneous cononary intervention

摘要: Treatment with 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improves short-and-long term prognosis in high-risk patients stable coronary artery disease and those acute syndrome their use is strongly recommended for secondary prevention. Moreover, recent data suggest that statin pre-treatment associated a better short- long-term outcome undergoing percutaneous intervention. Current guidelines revascularization recommend the of high-dose statins before intervention to reduce risk periprocedural myocardial infarction naive (class IIa A) on chronic therapy B). However, beneficial clinical effects elicited by angioplasty may arise not only from cardiac protection against injury but also renal kidney caused iodinated contrast media. Actually, exert multiple non-lipid lowering (pleiotropic) effects, including improved endothelial function, reduced inflammatory immuno-modulatory processes, oxidative stress platelet adhesion, contribute both cardio- nephro-protection even short-term.